STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $162,801 | -62.9% | 41,320 | 0.0% | 0.00% | – |
| Q2 2023 | $439,232 | +51.5% | 41,320 | +18.7% | 0.00% | – |
| Q1 2023 | $289,884 | +3.3% | 34,800 | +14.5% | 0.00% | – |
| Q4 2022 | $280,592 | -20.5% | 30,400 | +10.5% | 0.00% | – |
| Q3 2022 | $353,000 | +12.8% | 27,500 | +16.0% | 0.00% | – |
| Q2 2022 | $313,000 | -24.9% | 23,700 | +19.7% | 0.00% | – |
| Q1 2022 | $417,000 | -12.2% | 19,800 | 0.0% | 0.00% | – |
| Q4 2021 | $475,000 | +0.4% | 19,800 | +6.5% | 0.00% | – |
| Q3 2021 | $473,000 | -29.0% | 18,600 | -6.1% | 0.00% | – |
| Q2 2021 | $666,000 | -5.3% | 19,800 | +9.4% | 0.00% | – |
| Q1 2021 | $703,000 | -34.8% | 18,100 | +4.0% | 0.00% | -100.0% |
| Q4 2020 | $1,078,000 | +55.6% | 17,400 | -15.9% | 0.00% | – |
| Q3 2020 | $693,000 | +32.8% | 20,700 | -5.5% | 0.00% | – |
| Q2 2020 | $522,000 | +31.8% | 21,900 | +26.6% | 0.00% | – |
| Q1 2020 | $396,000 | – | 17,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |